{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:18:16Z","timestamp":1788430696632,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French National Public Health Agency"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Neisseria gonorrhoeae is a common bacterium responsible for sexually transmitted infections. The WHO recommends the use of 1\u2005g ceftriaxone to treat gonococcal infections. However, ceftriaxone-resistant strains are emerging, and carbapenems may be the last remaining treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared MICs for ceftriaxone, ertapenem, imipenem and meropenem in a collection of 81 clinical isolates and nine WHO reference isolates with various penA alleles. This previously characterized collection included nine ceftriaxone-resistant isolates. It was selected to include 42 different penA alleles (27 non-mosaic and 15 mosaic), 26 TEM penicillinase-producing isolates, five MDR and four XDR isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The MICs of ceftriaxone, ertapenem, imipenem and meropenem ranged from &amp;lt;0.002 to 2\u2005mg\/L, &amp;lt;0.002 to 0.064\u2005mg\/L, 0.008 to 1\u2005mg\/L and 0.002 to 0.125\u2005mg\/L, respectively. In ceftriaxone-resistant isolates, the MIC50 of ertapenem, imipenem and meropenem were 0.012\u2005mg\/L (0.004\u20130.032\u2005mg\/L), 0.75\u2005mg\/L (0.125\u20131\u2005mg\/L) and 0.032\u2005mg\/L (0.016\u20130.064\u2005mg\/L), respectively. For all antibiotics, MICs were significantly higher in isolates with a mosaic penA allele (P-value &amp;lt;0.001). No significant difference in carbapenem MICs was found between isolates with and without a TEM beta-lactamase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Carbapenem MICs remain low in N. gonorrhoeae isolates but are higher in those with mosaic penA alleles than in those with non-mosaic penA alleles. MICs for ertapenem are lower than those for other carbapenems, supporting its use for the treatment of infections with ceftriaxone-resistant N. gonorrhoeae. However, the establishment of breakpoints for carbapenem resistance in N. gonorrhoeae is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag201","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:48:12Z","timestamp":1788428892000},"source":"Crossref","is-referenced-by-count":0,"title":["<i>In vitro<\/i>\n                    carbapenem activity in\n                    <i>Neisseria gonorrhoeae<\/i>"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7817-7808","authenticated-orcid":false,"given":"Julie","family":"Brousseau","sequence":"first","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]},{"name":"IAME, INSERM1137, PrevIST Team, Paris Cit\u00e9 University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2562-7123","authenticated-orcid":false,"given":"Aymeric","family":"Braille","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9088-6789","authenticated-orcid":false,"given":"Mary","family":"Mainardis","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Meunier","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"M\u00e9rim\u00e8che","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]},{"name":"IAME, INSERM1137, PrevIST Team, Paris Cit\u00e9 University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-4802","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Cam\u00e9l\u00e9na","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]},{"name":"IAME, INSERM1137, PrevIST Team, Paris Cit\u00e9 University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1603-3635","authenticated-orcid":false,"given":"B\u00e9atrice","family":"Ber\u00e7ot","sequence":"additional","affiliation":[{"name":"Bacteriology Unit, Saint Louis-Lariboisi\u00e8re University Hospitals, APHP , Paris ,","place":["France"]},{"name":"Associated Laboratory for Gonococci, French National Reference Centre for Bacterial STI , Paris ,","place":["France"]},{"name":"IAME, INSERM1137, PrevIST Team, Paris Cit\u00e9 University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2026090305475805700_dlag201-B1","volume-title":"Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact","author":"Anon","year":"2021","edition":"1st ed"},{"key":"2026090305475805700_dlag201-B2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.10.2400113","article-title":"Sharp increase in gonorrhoea notifications among young people, EU\/EEA, July 2022 to June 2023","volume":"29","author":"Nerlander","year":"2024","journal-title":"Euro Surveill"},{"key":"2026090305475805700_dlag201-B3","author":"Anon"},{"key":"2026090305475805700_dlag201-B4","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S1473-3099(23)00479-6","article-title":"The enhanced gonococcal surveillance programme, Cambodia","volume":"23","author":"Ouk","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026090305475805700_dlag201-B5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3201\/eid3009.240557","article-title":"Emergence of extensively drug-resistant Neisseria gonorrhoeae, France, 2023","volume":"30","author":"Cam\u00e9l\u00e9na","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"2026090305475805700_dlag201-B6","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/S2666-5247(23)00370-1","article-title":"Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study","volume":"5","author":"Golparian","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026090305475805700_dlag201-B7","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1128\/AAC.00504-16","article-title":"New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan","volume":"60","author":"Nakayama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090305475805700_dlag201-B8","author":"Anon"},{"key":"2026090305475805700_dlag201-B9","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/jac\/dkae369","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015\u201324: an observational analysis","volume":"79","author":"Fifer","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026090305475805700_dlag201-B10","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420949126","article-title":"2020 European guideline for the diagnosis and treatment of gonorrhoea in adults","author":"Unemo","year":"2020","journal-title":"Int J STD AIDS"},{"key":"2026090305475805700_dlag201-B11","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.37.2300456","article-title":"Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023","volume":"28","author":"Maubaret","year":"2023","journal-title":"Euro Surveill"},{"key":"2026090305475805700_dlag201-B12","author":"Anon. Clinical and Laboratory Standards Institute (CLSI)"},{"key":"2026090305475805700_dlag201-B13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"2026090305475805700_dlag201-B14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/14787210.2025.2502799","article-title":"Letter to the editor regarding \u201cAlternative drugs for the treatment of gonococcal infections: old and new\u201d. Expert Review of Anti-infective Therapy 2024; 22(9): 753\u2013759","volume":"24","author":"Luckey","year":"2026","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026090305475805700_dlag201-B15","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1128\/AAC.00326-12","article-title":"In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090305475805700_dlag201-B16","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/jac\/dkt537","article-title":"Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime","volume":"69","author":"Quaye","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026090305475805700_dlag201-B17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026090305475805700_dlag201-B18","author":"Anon"},{"key":"2026090305475805700_dlag201-B19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"2026090305475805700_dlag201-B20","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1128\/AAC.47.5.1732-1735.2003","article-title":"Pharmacokinetics of intramuscularly administered ertapenem","volume":"47","author":"Musson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026090305475805700_dlag201-B21","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1093\/cid\/ciaf532","article-title":"The invisible tide of Neisseria gonorrhoeae treatment failures: a review and commentary","volume":"81","author":"Fagan","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026090305475805700_dlag201-B22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1473-3099(21)00625-3","article-title":"Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial","volume":"22","author":"de Vries","year":"2022","journal-title":"Lancet Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/5\/dlag201\/70937429\/dlag201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/5\/dlag201\/70937429\/dlag201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:48:13Z","timestamp":1788428893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag201\/8780972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag201","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"dlag201"}}